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ABSTRACT 
The observational and brief cross section study was conducted in the ADR monitoring centre, department of pharmacology, SVS MEDICAL 
HOSPITAL. The adverse drug reactions (ADR) reported by physician of dermatology department of SVSMH were collected and then causality, 
severity and preventability assessment was done. The results were presented as number and percentage. Total of 544 patients were observed 
with 15 suspected ADRs. The incidence of dermatological ADR was 3.78%. Maximum incidence of dermatological ADRs were observed with anti-
inflammatory agents and immunosuppressive (33.30%) followed by antibiotic drugs (13.3%).Dermatological adverse drug reactions were a 
common occurrence and awareness about them was found to be essential for early detection and prevention. The healthcare system can 
promote the spontaneous reporting of dermatological ADR top Pharmacovigilance centre's for ensuring safe drug use and patient care. . Most of 
the reported ADRs were possible, definitely preventable and mild in nature. Our study suggests that there is a need of intensive monitoring for 
ADRs in tertiary care hospital for early detection and to ensure the patient safety. 
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INTRODUCTION 
Adverse drug reactions are defined as any noxious 
unintended and undesired effects of a drug that occur at 
doses used for prevention, diagnosis or treatment1. 
An adverse drug reaction (abbreviated ADR) is an 
expression that describes harm associated with the use of 
given medications at a normal dosage during normal use 1. 
ADRs may occur following a single dose or prolonged 
administration of a drug or result from the combination of 
two or more drugs. The meaning of this expression differs 
from the meaning of "side effect", as this last expression 
might also imply that the effects can be beneficial.2 The study 
of ADRs is the concern of the field known 
as pharmacovigilance. An adverse drug 
event (abbreviated ADE) refers to any injury caused by the 
drug (at normal dosage and/or due to overdose) and any 
harm associated with the use of the drug (e.g. 
discontinuation of drug therapy).3 ADRs are a special type of 
ADEs. 
In everyday clinical practice, almost all physicians come 
across many instances of suspected adverse cutaneous drug 
reactions (ACDR) in different forms. Although such 
cutaneous reactions are common, comprehensive 
information regarding their incidence, severity and ultimate 
health effects are often not available as many cases go 
unreported. 
In the present world, almost every day a new drug enters 
market; therefore, a chance of a new drug reaction 
manifesting somewhere on some form in any corner of world 
is unknown on unreported. Although many a times 
,presentation is too trivial and benign, the early identification 
of the condition and identifying the culprit drug and omit it 
at earliest holds the keystone in management and prevention 
of a more severe drug rash. Therefore, not only the 
dermatologists, but all practicing physicians should be 
familiar with these conditions to diagnose them early and to 
be prepared to handle them adequately. Combined use of 
multiple drugs may cause adverse events. Drug interactions 
can lead to an increase or a decrease of the drug effects or 
cause other serious reactions. For example, co 
administration of a drug metabolized by Cytochrome P450 
3A4 (CYP3A4) and the drug inhibiting CYP3A4, such as 
cyclosporine and clarithromycin, respectively, result in 
delayed clearance and elevated blood levels of the former 
drug, which increases and prolongs both the therapeutic and 
adverse effects4 A common misconception is that a drug’s 
effects can be clearly divided into two categories : desired(or 
therapeutic effects) and undesired (or side effects).Actually 
,most drugs produce several effects ,but a physician usually 
wants a experience only one (or a few) of them; the other 
effects are hence regarded as undesired. Although most 
people including healthcare practitioners use the term ‘side 
effect’, the term ‘adverse drug reaction’ is more 
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appropriate for effects that are undesired, unpleasant, 
noxious or potentially harmful. 
 Although many of the ADR’s are relatively mild and 
disappear when the drug is stopped or the dose is 
reduced, others are more serious and long lasted. 
Therefore, there is little doubt that ADR’s increase not 
only morbidity and mortality, but also add to the overall 
healthcare cost 7,8. 
Some ADR’s are predictable in nature especially those where 
a contraindicated drug is used (in patient with a known 
allergy or with co-morbidities contraindicating its use) or 
the wrong dose of a drug administered. The importance of 
understanding the predictability of an ADR was first 
reviewed in 1971. Where it was estimated that 70-80% of 
ADR’s are predictable and may be preventable .It is true that 
some ADR’s are unavoidable and will occur even with the 
most extraordinary precautions in place. However, a large 
proportion of ADR’s may be preventable. Yet, in most 
hospitals today, too little is done to identify and understand 
preventable ADR’s. This information is of utmost importance 
for guiding educational programs and systems to facilitate a 
reduction in the number of ADR’s that occur. The 
[preventability of ADR’s is an appropriate data element 
which can be fed back into the system to facilitate the 
improvement process. 
Importance of ADR reporting in India:  
Adverse Drug Reactions are fourth to sixth leading cause of 
death among hospitalized patients and it occurs in 0.3 per 
cent to 7 per cent of all hospital admissions. The incidence of 
serious ADR’s is 6.7 percent 5]. There is a rapid increase in 
the number of new drugs entering the market from last few 
decades India being the second most populated country has 
over one billion potential drug consumers, and no amount of 
pre-clinical and clinical data is sufficient to conclude the 
complete safety of a drug, under this scenario it becomes 
necessary to report any untoward reaction of any 
pharmaceutical product to assess its safety and efficacy to 
ensure maximal patient health. 
METHODOLOGY 
Study location: 
The study will be carried out in the S.V.S Medical college & 
Hospital including both outpatient and inpatient 
departments.  
Study design: 
The study will be an observational type, prospective and 
descriptive type. 
Study Period: 
Study period will be of 6 months (November 2014 to March 
2015). 
Study Setting: 
Study will be based only on those patients who experience 
an adverse reaction to medicine used either during their stay 
in hospital (IPD) or visiting the outpatient departments 
(OPD) of dermatology. 
Study Criteria: 
Inclusions: 
 Patient’s name, age, gender. 
 Drug Prescribed. 
 Dosage of Drugs Prescribed & dosage form. 
 Route of Administration. 
Exclusions: 
 Incomplete information regarding patient. 
Data collection: 
Data on the Reported ADRs will be evaluated to understand 
the pattern of the ADRs with respect to patient demographic 
disease, Nature of the reactions, characteristics of the drugs 
involved, and outcome of the reactions. 
Criteria for identifying ADRs: 
ADR identified by physicians will be considered and will be 
included in the study. 
Analysis of ADRs: 
The total number of ADRs reported. 
Nature and description of ADDRs reported. 
Causality assessment of ADR based on Algorithm 9,10. 
       The degree of association of an adverse of an adverse reaction 
with a drug is done    with the help of Naranjo’s algorithm. 
Severity of ADRs: 
After the causality assessment has been done, the severity of 
the ADR is analyzes using adapted Hart wig severity scale. 
The Scale is classified as: 
1. Mild: A reaction that does not required treatment or 
hospital stay. 
2. Moderate:  A reaction that requires treatment and or 
prolongs hospitalization by at least one day. 
3. Severe: A reaction that is potentially life threatening or 
contributes to the death of patient is permanently 
disabling requires intensive medical care or results in a 
congenital anomaly cancer or unintentional overdose. 
To study the onset of ADRs: 
1. Acute:  Acute events are those which are observed within 
60 minutes after the administration of medication. 
2. Sub-Acute: These occur within 1-24 hours from the time f 
administration of     medication. 
3. Latent: These reactions take 2 more days to become 
apparent. 
Preventability of ADRs: 
Complete preventability of ADR is not possible, but some of 
the ADR can be preventable if that ADR can give at least one 
answer of Schumock and Thornton Scale. 
Predictability of ADRs: 
Patients who have had the drug on previous occasion(s): If 
the drug was previously well-tolerated at the same dose and 
route of administration, the ADR is NOT PREDICTABLE; 
there was a history of allergy or previous reaction to the 
drug, the ADR is PREDICTABLE. Patients who have never had 
the drug previously: Incidence of the ADR reported in 
product information or other literature determines its 
predictability. 
Statistical analysis: 
 All the data collected during the study will be processed 
using SPSS software. 
 All the data will be represented as average (±SEM) and 
percentages, 
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 Rates of ADR or ADR occurrence during the hospital 
stay will be calculated as percentage of in-patient or 
out-patient population treated. 
 Student’s t-test will be use to compare mean values. 
RESULTS & DISCURSION 
Assessment of ADR according to gender: 
Female number of patients:                 250 
Male number of patients:                     294 
Total number of patients:                     544 
Female number of ADRs:                      04 
Male number of ADRs:                          11 
Total number of ADRs:             15 
 
 
Figure 1: graphical representation of ADR according to 
gender 
 
Table 1: Age distribution of the patients among male and female: 
Frequency Male Female No. ADR Percentage 
0 – 10 24 17 03 7.3% 
11 – 20 69 56 04 3.2% 
21 – 30 94 92 05 2.6% 
31 – 40 43 46 02 2.2% 
41 – 50 25 52 00 0% 
51 – 60 16 10 00 0% 
61 – 70 19 03 01 4.5% 
71 – 80 04 01 00 0% 
 
Table 2.Pharmacological class Vs number of ADRs in patients: 
Pharmacological class Number of patients Percentage of patients 
NSAIDs 02 13.3% 
Local anesthetic agent 02 13.3% 
Anti-inflammatory and 
immunosuppressive 
05 33.3% 
Anti-biotic  02 13.3% 
Anti-convulsant 01 6.6% 
Anti-cancer 01 6.6% 
Ayurvedic medicine  01 6.6% 
Anti-fungal 01 6.6% 
 
Table 3: Casualty assessment 
Casualty Number of patients Male Female 
Definite 07 05 02 
Probable 07 05 02 
Possible 01 00 01 
Unlikely 00 00 00 
 
Table 4: Severity of ADR distribution: 
 
 Severity 
Number of patients Male Female 
Mild 11 8 3 
Moderate 2 1 1 
Severe 2 2 0 
Fatal 0 0 0 
 
 
 
 
 
 
 
Female 250 
Female ADR 1.6% 
Male 294 
Male ADR 3.74 
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Table 5: the particular relating to cutaneous ADRs: 
S.N
o 
Age Gende
r 
Drug name Route of 
administra
tion 
Category Type of ADR Dose Category 
severity 
1. 08 M Ofloxacin Oral anti-biotic Type A- Dose 
dependent 
200 mg Sever 
Level-5 
2. 14 F Metronidazole Oral anti-biotic Type A- Dose 
dependent 
200 mg Moderate 
Level-4 
3. 70 M Clorambucil Oral Anti-cancer Type-B- 
 Idiosyncratic 
2 mg Severe 
Level-5 
4. 33 F Diclofinac sodium Oral NSAIDs Type-B- 
 Idiosyncratic 
50 mg Mild 
Level-2 
5. 30 M Lignocaine Cutaneous Local anesthetic Type-H hyper 
sensitivity 
½ cc 
(30% v/v) 
Mild 
Level-2 
6. 27 M Lignocaine Cutaneous Local anesthetic Type-H hyper 
sensitivity 
½ cc 
(30% v/v) 
Mild 
Level-2 
7. 25 F Ayurvadic 
medicine  
Oral - Type-F – 
therapy 
failure 
- Mild 
Level-2 
8. 28 M Clobetasol 
propionate  
Topical Anti-inflammatory & 
immunosuppressive 
Type-B- 
 Idiosyncratic 
0.05% Moderate 
Level-4  
9. 36 M Clotrimazole Topical Antifungal Type-B- 
 Idiosyncratic 
5 gm 
(0.5 w/w) 
Mild 
Level-2 
10. 10 F Betamethasone 
dipropionate 
Topical Anti-inflammatory & 
immunosuppressive 
Type-H hyper 
sensitivity 
20gm 
(0.05%w/w) 
Mild 
Level-2 
11. 16 M Betamethasone 
dipropionate 
Topical Anti-inflammatory & 
immunosuppressive 
Type-H hyper 
sensitivity 
20 gm 
(0.2%w/w) 
Mild 
Level-2 
12. 20 M Beclomethasone Topical Anti-inflammatory & 
immunosuppressive 
Type-F – 
therapy 
failure 
5gm (0.025 
% w/w) 
Mild 
Level-2 
 
13. 19 M Betamethasone 
volerate 
Topical Anti-inflammatory & 
immunosuppressive 
Type-B- 
 Idiosyncratic 
20gms 
(0.01%) 
Mild 
Level-2 
14. 06 M Sodium valproate Oral Anti-conversant Type-B- 
 Idiosyncratic 
100ml 
(200mg) 
Mild 
Level-2 
15. 28 M Diclofinac sodium Oral NSAIDs Type-H hyper 
sensitivity 
150mg Mild 
Level-2 
 
CONCLUSION 
ADRs are potentially avoidable causes for seeking medical 
attention. They increase the burden of work and can be fatal 
at times adding to the common person's negative perception 
of allopathy. With the number of drugs being marketed 
increasing every year, it is of paramount importance to have 
an in-depth knowledge of their possible adverse reactions 
and this is possible only when the physician is trained 
adequately and have  knowledge on incidence of various 
adverse drug reactions. There are variations in the results in 
comparison to other studies like female predominance, 
offending drugs like among antimicrobials were found to be 
commonly involved. Among different medications anti-
inflammatory group and antibiotics were commonly 
responsible drugs. Causality assessment also resulted in high 
score of definite category. A robust mechanism for reporting 
of ADRs is required while the clinician is to be always on the 
lookout for ADRs. So, anticipating, preventing, recognizing 
and responding to ADRs should be the prime concern of the 
clinicians so as to minimize the incidence of ADRs. 
Results of this study emphasized the need of ADR reporting 
in tertiary care hospitals to help in assessing the benefit risk 
ratio of drugs. From this study, it had been concluded that 
incidence of ADRs occurrence was high in female patients.  
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